Raltegravir 600 mg Drug Discount Agreement
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Raltegravir 600 mg (ATC-Code nach WHO: J05AJ01)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed volumes; actual purchases depend on prescription behavior and patient numbers.
Buyer may terminate open-house if exclusive agreements are concluded (typically 8-12 months after publication), ending...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jun 30, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Supply of pharmaceutical product Raltegravir 600 mg (ATC J05AJ01)
- Non-exclusive discount agreement under §130a Abs. 8 SGB V
Show full summary
This tender is for non-exclusive drug discount agreements (Rabattvereinbarungen) under §130a Abs. 8 SGB V for the active substance Raltegravir 600 mg (ATC J05AJ01) via an open-house model. The buyer is AOK PLUS, a German health insurance fund. The agreement is a framework agreement with no guaranteed minimum purchase volumes. The contract runs until June 30, 2028, and the procedure allows any qualified pharmaceutical company to participate at any time by meeting the eligibility criteria. No estimated value is provided, and the award is not based on typical procurement criteria. The notice explicitly states it is not a standard EU procurement but published for transparency.
Risks
No guaranteed volumes; actual purchases depend on prescription behavior and patient numbers.
Buyer may terminate open-house if exclusive agreements are concluded (typically 8-12 months after publication), ending...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical enterprise as defined in §4 Abs. 18 AMG
- Must not be subject to EU sanctions against Russia (Regulation 833/2014)
Eligibility
- Must submit self-declaration on exclusion grounds (§§123, 124 GWB)
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Raltegravir 600 mg Drug Discount Agreement
Non-exclusive discount agreement for Raltegravir 600 mg (ATC J05AJ01) under an open-house model. No minimum quantities guaranteed. Delivery to Saxony and Thuringia, Germany.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Raltegravir 600 mg (ATC-Code nach WHO: J05AJ01)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 07 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 236436-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed volumes; actual purchases depend on prescription behavior and patient numbers.
Buyer may terminate open-house if exclusive agreements are concluded (typically 8-12 months after publication), ending...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications